Michael J. Evans
University of California, San Francisco
H-index: 32
North America-United States
Top articles of Michael J. Evans
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
SENTRI: Single-particle energy transducer for radionuclide injections for personalized targeted radionuclide cancer therapy | International Journal of Radiation Oncology* Biology* Physics | Kyoungtae Lee Rahul Lall Shalini Chopra Michael J Evans Michel M Maharbiz | 2024/4/1 |
Low cost, high temporal resolution optical fiber-based γ-photon sensor for real-time pre-clinical evaluation of cancer-targeting radiopharmaceuticals | Biosensors and Bioelectronics | Rahul Lall Kyoungtae Lee Shalini Chopra Averal Kandala Michael Evans | 2024/3/1 |
Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer | 2023/2/9 | ||
Dosimetry Reconstruction in Radiopharmaceutical Therapy Using a Sparse Network of External γ-Sensors | International Journal of Radiation Oncology, Biology, Physics | R Lall M Evans Y Seo A Niknejad M Anwar | 2023/10/1 |
Imaging granzyme biochemistry in CAR T cell immunotherapy with restricted interaction peptide and PET | Shalini Chopra Michael Evans Sasank Sakhamuri Charles Craik Arun Witta | 2023/6/1 | |
Modulators of resistant androgen receptor | 2023/8/29 | ||
Developing a targeted radiotherapy platform with a proteolytically activated membrane binding radiopharmaceutical | Garima Arvikar Apurva Pandey Conner Bardine Nima Hooshdaran Sasank Sakhamuri | 2023/6/1 | |
Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer | Clinical Cancer Research | Shalini Chopra Kai Trepka Sasank Sakhamuri Alberto Carretero-González Jun Zhu | 2023/4/3 |
Chemoenzymatic Syntheses of Fluorine-18-Labeled Disaccharides from [18F] FDG Yield Potent Sensors of Living Bacteria In Vivo | Journal of the American Chemical Society | Alexandre M Sorlin Marina López-Álvarez Sarah J Rabbitt Aryn A Alanizi Rebecca Shuere | 2023/8/3 |
Elevated labile iron in castration–resistant prostate cancer is targetable with ferrous iron–activatable antiandrogen therapy | European Journal of Medicinal Chemistry | Ryan L Gonciarz Sasank Sakhamuri Nima Hooshdaran Garima Kumar Hyunjung Kim | 2023/3/5 |
Covalent proteins as targeted radionuclide therapies enhance antitumor effects | ACS central science | Paul C Klauser Shalini Chopra Li Cao Kondapa Naidu Bobba Bingchen Yu | 2023/6/7 |
Preclinical evaluation of theranostic strategy using nanoplatform and transferrin to target hyperactivity of cMYC in the context of non-small cell lung cancer | Médecine Nucléaire | S Martin Aubert M Richard D Kereselidze M Evans B Kuhnast | 2023/3/1 |
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial | The Lancet Oncology | Rahul Aggarwal Stephanie Starzinski Ivan de Kouchkovsky Vadim Koshkin Rohit Bose | 2023/11/1 |
Restricted Interaction Peptides as an imaging tool for viral and bacterial infections | Apurva Pandey Shalini Chopra Simon Cleary Sasank Sakhamuri David Wilson | 2023/6/1 | |
Rheumatology Informatics System for Effectiveness (RISE) practices see significant gains in rheumatoid arthritis quality measures | Arthritis care & research | Zara Izadi Gabriela Schmajuk Milena Gianfrancesco Meera Subash Michael Evans | 2022/2 |
CUB domain containing protein 1 is a target for radioligand therapy in multiple bladder cancer subtypes, including Nectin-4 and TROP2 null disease | Shalini Chopra James Wells Jie Zhou Jonathon Chou Michael Evans | 2022/6/1 | |
Impact of radiolabeling strategies on the pharmacokinetics and distribution of an anti-PD-L1 PET ligand | Molecular Pharmaceutics | Vu Long Tran Alizée Bouleau Hervé Nozach Mylène Richard Céline Chevaleyre | 2022/8/23 |
In Vivo Profiling with 18F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions | Molecular Pharmaceutics | Hyunjung Kim Yangjie Huang Ning Zhao Yung-hua Wang Sasank Sakhamuri | 2022/1/20 |
Getting a GRIP on antitumor immunity with granzyme targeted PET | Michael Evans Charles Craik Ning Zhao Conner Bardine | 2022/6/1 | |
Optimizing Immuno-PET imaging of tumor PD-L1 expression: pharmacokinetic, Biodistribution, and Dosimetric comparisons of 89Zr-labeled anti-PD-L1 antibody formats | Journal of Nuclear Medicine | Alizée Bouleau Hervé Nozach Steven Dubois Dimitri Kereselidze Céline Chevaleyre | 2022/8/1 |
Co-Authors
